According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

Published Date: 09 Jun 2023

Italy: Deep, long-lasting responses and sustained survival seen with fixed-duration ibrutinib plus venetoclax are maintained in high-risk patients.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An FDA panel supports the use of CAR T-cell therapy earlier in the treatment of multiple myeloma.

2.

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

3.

Extracellular matrix pathway emerges as treatment target for pediatric cancer

4.

Are ultramarathon runners really at increased risk of bowel cancer?

5.

Study: Rapamycin slows the progression of cancer by reducing aging and concentrating on precancerous cells.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot